In a report published Wednesday, Bank of America Merrill Lynch reiterated its Buy rating on Eli Lilly & Co. LLY, and raised its price target from $57.00 to $60.00.
BofA Merrill Lynch noted, “LLY offers a good mix of compelling valuation, an attractive dividend yield with a track record of returning cash to shareholders, and pipeline optionality. Several promising late-stage pipeline assets are underappreciated, in our view, and could be transformative to LLYs growth trajectory (ramucirumab, solanezumab and the four Phase III diabetes assets - two basal insulins, empagliflozin and dulaglutide).”
Eli Lilly & Co. closed on Tuesday at $51.88.
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
date | ticker | name | Price Target | Upside/Downside | Recommendation | Firm |
---|
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in